Skip to main content
Clinical Trials/NCT00708526
NCT00708526
Completed
Not Applicable

Improved Patient Recovery After Anesthesia With Hypercapnia Hyperpnoea

University of Utah1 site in 1 country22 target enrollmentMarch 2008
ConditionsHypercapnia

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Hypercapnia
Sponsor
University of Utah
Enrollment
22
Locations
1
Primary Endpoint
Recovery From Anesthesia
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

The proposed study will measure the time from the end of surgery until the time patients meet the discharge criteria from the postoperative anesthesia care unit and the time from the end of surgery until the patients regained cognitive function after anesthesia.

Detailed Description

Hypercapnia has been used in conjunction with hyperpnoea to provide a more rapid return of responsiveness after inhaled anesthesia. In our first clinical study with isoflurane we confirmed that the time from turning off the vaporizer to opening of eyes was shortened by an average of 62% when the minute ventilation was elevated and the end tidal carbon dioxide concentration was kept at 52 mmHg rather than 28 mmHg during emergence. In our second study we found that hypercapnia and hyperpnoea accelerated recovery proportionately for sevoflurane and desflurane. The benefits of accelerating subject recovery in the operating room may extend to the entire recovery period if the subject is more alert and easier to care for when they arrive in the post anesthesia care unit.

Registry
clinicaltrials.gov
Start Date
March 2008
End Date
November 2008
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • ASA class I-III
  • both genders
  • scheduled to undergo eye surgery at the Moran Hospital.

Exclusion Criteria

  • a history of renal or hepatic disease,
  • chronic alcohol or drug abuse,
  • disabling neuropsychiatric disorder,
  • hypersensitivity or unusual response to other halogenated anesthetics,
  • pulmonary hypertension,
  • increased intracranial pressure,
  • seizure disorder
  • personal/familial history of malignant hyperthermia.
  • currently being treated with known hepatic enzyme-inducing drugs (e.g., phenobarbital, dilantin or isoniazid)
  • or with drugs known to alter anesthetic requirements (e.g., opiates, clonidine, alpha2 agonists, alcohol, anticonvulsants, antidepressants, barbiturates, benzodiazepines or other tranquilizers).

Outcomes

Primary Outcomes

Recovery From Anesthesia

Time Frame: up to 2 hours

average time in minutes from the time the surgeon finished closing the surgical incision until the time the investigator in the postoperative care unit determined that the patients meet the discharge criteria from the postoperative anesthesia care unit (their vital signs had been stable for at least 30 min, their pain scores were less than the tolerable pain scores, they could sit up without dizziness or nausea, and their Aldrete score was ≥8).

Secondary Outcomes

  • Return of Cognitive Function(up to 30 minutes)

Study Sites (1)

Loading locations...

Similar Trials